Comparison · NCT02993731-deaths
Napabucasin Plus Nab-paclitaxel With Gemcitabine (Safety Population) vs Nab-paclitaxel With Gemcitabine (Safety Population): deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Napabucasin Plus Nab-paclitaxel With Gemcitabine (Safety Population) vs Nab-paclitaxel With Gemcitabine (Safety Population): deaths from any cause. Trial comparisons, record NCT02993731-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02993731-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.747 | 0.709 | 0.781 | wilson | |
| Risk in group 2 | 0.731 | 0.693 | 0.767 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0156 | -0.036 | 0.0673 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.02 | 0.952 | 1.1 | log | |
| Odds ratio, group 1 over group 2 | 1.08 | 0.829 | 1.42 | log | |
| Number needed to harm, for one more death from any cause on Napabucasin Plus Nab-paclitaxel With Gemcitabine (Safety Population) than on Nab-paclitaxel With Gemcitabine (Safety Population) | 64 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Napabucasin Plus Nab-paclitaxel With Gemcitabine (Safety Population) | All participants who received at least 1 dose of napabucasin administered orally, twice daily in combination with weekly nab-paclitaxel and gemcitabine administered intravenously, once weekly, on 3 of every 4 weeks. | 419 | 561 | EG000 |
| Group 2 | Nab-paclitaxel With Gemcitabine (Safety Population) | All participants who received at least 1 dose of nab-paclitaxel and gemcitabine administered intravenously, once weekly, on 3 of every 4 weeks. | 400 | 547 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
Every 1-2 weeks from date of screening until protocol treatment discontinuation. Following permanent protocol treatment discontinuation, every 8 weeks, starting with the 4 week post-protocol treatment discontinuation visit, up to 36 months.
Source ClinicalTrials.gov
Trial
- Title
- A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma
- NCT number
- NCT02993731
- Phases
- PHASE3
- Conditions
- Carcinoma, Pancreatic Ductal
- Interventions
- Napabucasin, Nab-paclitaxel, Gemcitabine
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Results first posted
- 2021-06-10
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02993731?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02993731-deaths